Clinical Trial

Toripalimab With Chemotherapy for Sinus Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers. The names of the study drugs used in this research study are: * Toripalimab (a type of monoclonal antibody) * Carboplatin (a type of antineoplastic agent) * Docetaxel (a type of antineoplastic agent) * Cisplatin (a type of antineoplastic agent)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-15; most recent amendment 2025-06-25.
Status change: Not Yet Recruiting → Recruiting 2025-06-25
Trial Details
NCT Number NCT06940180
Lead Sponsor Glenn J. Hanna
Collaborators: Coherus Oncology, Inc.
Conditions Sinonasal Cancer, Paranasal Sinus Neoplasms, Squamous Cell Carcinoma, Sinonasal Undifferentiated Carcinoma, Locally Advanced Head and Neck Cancer
Enrollment 20 participants
Start Date 2025-06-17
Primary Completion 2028-02-01 (estimated)
Study Completion 2029-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-26